PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerviewpress.com
Lesley Camille Ballance, MSN, FNP-BC / Amy Goodrich, CRNP / Jill Lozensky, RN, BSN, OCN - Changing Times in DLBCL: Oncology Nurse Insight on the Practicalities of Antibody Therapy
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.